Navigation Links
Discovery Labs Presents Surfaxin and Aerosurf Data At the Pediatric,Academic Societies' Annual Meeting

tions, risks that the Chemical, Manufacturing and Controls section of Discovery's New Drug Application will not satisfy the FDA, risks relating to the ability of Discovery or Discovery's third party manufacturers and development partners to manufacture or provide Discovery with adequate supplies of drug substances and expertise for completion of any of Discovery's clinical studies, risks related to the ability of Discovery and its collaborators to develop, manufacture and successfully commercialize products that combine Discovery's drug products with innovative aerosolization technologies, risks relating to drug manufacturing by Discovery, risks relating to the significant, time-consuming and costly research, development, pre-clinical studies, clinical testing and regulatory approval process for any products that Discovery may develop independently or with Discovery's collaboration arrangements, risks relating to the development by other companies of competing therapies and/or technologies, risks relating to reimbursement and health care reform, and risks relating to securities, product liability and other litigation. Companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in advanced clinical trials, even after obtaining promising earlier trial results. Data obtained from tests are susceptible to varying interpretations, which may delay, limit or prevent regulatory approval. Those associated risks and others are further described in Discovery's filings with the Securities and Exchange Commission including the most recent reports on Forms 10-K, 10-Q and 8-K, and any amendments thereto.

Company Contact: Lisa Caperelli, Investor Relations 215-488-9413


'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
2. Discoverys KL-4 Surfactant Technology Demonstrates Novel Anti-Inflammatory Properties
3. Major Discovery Raises Prospect of Better Patient Care By Improving Platelet Life Span
4. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
5. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
6. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
7. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
8. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
9. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
10. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
11. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
Post Your Comments:
(Date:1/15/2014)... CAMBRIDGE, Mass. , Jan. 15, 2014  Zafgen, ... the unmet needs of severely obese patients, today ... of beloranib, a selective inhibitor of methionine aminopeptidase ... a severe form of genetic obesity.  These results ...
(Date:1/14/2014)... , Jan. 14, 2014 The Brandeis Medical Center, led ... a premier and affordable laser tattoo removal experience with ... Brandeis, focus is in providing high quality cosmetic services with cutting ... " Southern California has seen a ...
(Date:1/14/2014)... , Jan. 14, 2014 NineSigma , Inc., ... its Innovation Leadership Summit , May 14-16, 2014 ... Cleveland Ohio . This ... organizations committed to breakthrough achievements through open innovation. Participants ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4
... Cardica, Inc. (Nasdaq: CRDC ) today announced ... Proximal Anastomosis System will be featured in several demonstration ... and Hybrid Coronary Revascularization conference, a meeting jointly developed ... Joseph,s Hospital in Atlanta, Georgia. "This ...
... announced that it has received approval from the United ... 7,815,929) regarding a method for the preparation, storage and ... nature, the process of compounding suppositories is cumbersome, time-consuming ... Muni, founder, chairman, and CEO of CutisPharma, Inc. "Our ...
Cached Medicine Technology:Cardica's Automated Anastomosis Systems Featured at Advances In Robotic And Hybrid Coronary Revascularization Meeting 2Cardica's Automated Anastomosis Systems Featured at Advances In Robotic And Hybrid Coronary Revascularization Meeting 3CutisPharma Announces Issuance of an Additional Patent for Suppository Compounding 2
(Date:4/17/2014)... have identified new pain relief targets that could ... BBSRC-funded researchers at King,s College London made the ... in the periphery of the body. , Dr ... identifying mechanisms underlying pain generation and our findings ... side effects." , One potential side effect of ...
(Date:4/17/2014)... Two recent papers by a University of ... help scientists develop treatments or vaccines for Dengue ... and other disease-causing flaviviruses. , Jeffrey S. Kieft, ... at the School of Medicine and an early ... and colleagues recently published articles in the scholarly ...
(Date:4/17/2014)... (April 17, 2014) Doctors who treat patients ... lymphangioleiomyomatosis (LAM) can face an agonizing treatment decision. ... the disease and help relieve shortness of breath. ... and sirolimus can cause potentially fatal complications following ... Dr. Daniel Dilling, medical director of Loyola University ...
(Date:4/17/2014)... (BUSM) have discovered that the anti-seizure drug ezogabine, ... findings, reported in the American Journal of ... more effective treatments for alcoholism. , Excessive consumption ... of illness and death in the U.S. and ... productivity of workers and necessitating huge health care ...
(Date:4/17/2014)... NEW YORK (17 April 2014) Population Council scientists and ... is safe, stable, and can prevent the transmission of ... and rectum in animals: HIV, herpes simplex virus 2 ... provides the first data that the gel is effective ... of efficacy in the vagina against all three viruses ...
Breaking Medicine News(10 mins):Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2
... Demand for Dark Chocolate by Active, On-the-Go Consumers , , ... Fueled by demand for nutritious, yet delicious snacks, Abbott ... ZonePerfect (R) Dark Chocolate Nutrition Bars - Dark ... Creme. , , Made with real cacao, ZonePerfect ...
... YORK, June 2 , ... 1991 , PharmaPendium ( http://www.info.pharmapendium.com/ ... drug,information, has significantly expanded its coverage of US Food ... the FDA Classic,Collection. This collection contains all available historical ...
... for Focus, Performance and Recovery , , HUNTINGTON BEACH, ... high-performance sports water designed ... to give them an edge, in terms of focus, better ... , , "With AquaHydrate, we believe ...
... be used to perform several screens, researchers say , TUESDAY, ... stool can accurately screen for more types of cancer than ... DNA stool testing has been successfully used for early detection ... that the noninvasive screening is also good at finding other ...
... researchers have demonstrated that a noninvasive screening test can detect ... the colon -- including pancreas, stomach, biliary and esophageal cancers. ... being presented at Digestive Disease Week 2009 in Chicago, May ... for approximately one in four cancer deaths. While high cure ...
... 2 June 2009 -- PharmaPendium ( http://www.info.pharmapendium.com ), ... drug information, has significantly expanded its coverage of US ... launch of the FDA Classic Collection. This collection contains ... including those issued in 1991 all indexed and ...
Cached Medicine News:Health News:Three New ZonePerfect(R) Dark Chocolate Nutrition Bar Flavors Fuel Satisfying and Delicious Snacking 2Health News:Three New ZonePerfect(R) Dark Chocolate Nutrition Bar Flavors Fuel Satisfying and Delicious Snacking 3Health News:Three New ZonePerfect(R) Dark Chocolate Nutrition Bar Flavors Fuel Satisfying and Delicious Snacking 4Health News:Elsevier's PharmaPendium(TM) Introduces the FDA Classic Collection 2Health News:Elsevier's PharmaPendium(TM) Introduces the FDA Classic Collection 3Health News:The First High-Performance Sports Water, AquaHydrate, Delivers Cellular Hydration and Electrolytes, Naturally 2Health News:The First High-Performance Sports Water, AquaHydrate, Delivers Cellular Hydration and Electrolytes, Naturally 3Health News:The First High-Performance Sports Water, AquaHydrate, Delivers Cellular Hydration and Electrolytes, Naturally 4Health News:Simple Test Could Detect More Gastrointestinal Cancers 2Health News:Improved DNA stool test could detect digestive cancers in multiple organs 2Health News:Improved DNA stool test could detect digestive cancers in multiple organs 3Health News:Elsevier's PharmaPendium introduces the FDA Classic Collection 2
BD Persist Plus protective barrier skin preps with chlorhexidine in alcohol...
... Sterile Isopropyl Alcohol 70% USP and 10% ... as a topical antiseptic, anti-infective prior to ... removal of oils and fats from the ... AAMI/ANSI/ISO 11137 standards to contain a consistent ...
Aplicare's Prep Pads offer convenience, low cost, ease of use. The medium size is appropriate for most applications. Each package is terminally sterilized, ensuring the safest possible product for th...
IV Prep Swab Sticks are effective, easy to apply, dries quickly and reduces bacterial contaminations. They are ideal for preparation of the skin prior to a ventipuncture or injection....
Medicine Products: